Major Take-Away From This Study:
# Covid Impact on Pharmaceutical Drug Delivery Market, growth/decline in product type/use cases of Pharmaceutical Drug Delivery Market due to cascaded impact of Covid on Extended Ecosystem.
# How top 50 companies in Pharmaceutical Drug Delivery Market are making rapid shifts in their strategies as we speak here.
# Outside-in view of top 50 companies client and client’s clients shifting short-term priorities.
This market is projected to reach USD 2,015.3 billion by 2025 from USD 1,430.5 billion in 2020, at a CAGR of 7.1% during the forecast period.
Growth in this market is mainly driven by the rising prevalence of chronic diseases, growth in the biologics market, and technological advancements and new product launches. Due to the outbreak of corona virus globally, there is a sudden rise in the demand for pharmaceutical drugs largely in infectious application.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085
In 2019, the infectious diseases segment accounted for the largest share
Based on application, the pharmaceutical drug delivery market is segmented into infectious diseases, cancer, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications.
In 2019, the infectious diseases segment accounted for the largest share of the pharmaceutical drug delivery market. The large share of this segment can be majorly attributed to the increasing prevalence of infectious diseases and increasing company initiatives to enhance R&D related to infectious diseases. Further, spread of COVID-19 has further propelled the market for this application.
Recent Developments in Global Industry:
# In 2020, Johnson & Johnson, Inc collaborated with Biomedical Advanced Research and Development Authority (BARDA), to expedite development and strengthen access through production of coronavirus vaccine.
# In 2020, Johnson & Johnson, Inc collaborated with MeiraGTx Holdings Plc (US) to develop, manufacture and commercialize its clinical stage inherited retinal disease drug portfolio.
# In 2019, Novartis signed an agreement with Shionogi (Japan) to commercialize new treatment, Rizmoic (Naldemedine) for Opiod-induced constipation in key European countries of Germany, UK and Netherlands, with rights of first refusal for some other European markets.
North America was the largest regional market for pharmaceutical drug delivery in 2019
The global pharmaceutical drug delivery market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the market.
The large share of the North American market can be attributed to factors such as growth in biologics in the pharmaceuticals market; the rising prevalence of chronic diseases increasing patient compliance to innovative drug delivery technologies; and the presence of a large number of prominent players in this region.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085
Major Leaders:
The pharmaceutical drug delivery market is highly fragmented in nature with several big and emerging players. Johnson & Johnson, Inc. (US), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Pfizer, Inc. (US), Sanofi (France), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), 3M (US), Antares Pharma, Inc. (US), and Becton, Dickinson and Company (BD) (US) are some of the leading players operating in the global pharmaceutical drug delivery market.
Players in this market pursue the strategies of product approvals, partnerships, agreements, collaborations, expansions, and acquisitions to develop and expand their market presence. Product approvals has been the key growth strategy adopted by players to expand their share in the market.
